Vanguard Group
CGEM icon

Vanguard Group’s Cullinan Oncology CGEM Stock Holding History

Vanguard Group’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$34.1M Buy
3,298,504
+355,179
+12% +$3.2M ﹤0.01% 2372
2025
Q3 		$17.5M Sell
2,943,325
-76,775
-3% -$562K ﹤0.01% 2693
2025
Q2 		$22.7M Sell
3,020,100
-19,631
-0.6% -$158K ﹤0.01% 2500
2025
Q1 		$23M Buy
3,039,731
+103,504
+4% +$993K ﹤0.01% 2449
2024
Q4 		$35.8M Sell
2,936,227
-62,487
-2% -$898K ﹤0.01% 2307
2024
Q3 		$50.2M Buy
2,998,714
+127,339
+4% +$2.26M ﹤0.01% 2178
2024
Q2 		$50.1M Buy
2,871,375
+1,097,030
+62% +$23.4M ﹤0.01% 2141
2024
Q1 		$30.2M Buy
1,774,345
+2,902
+0.2% +$44.8K ﹤0.01% 2392
2023
Q4 		$18.1M Buy
1,771,443
+82,910
+5% +$734K ﹤0.01% 2643
2023
Q3 		$15.3M Sell
1,688,533
-338,873
-17% -$3.53M ﹤0.01% 2664
2023
Q2 		$21.8M Sell
2,027,406
-527,582
-21% -$5.6M ﹤0.01% 2552
2023
Q1 		$26.1M Sell
2,554,988
-257,977
-9% -$2.84M ﹤0.01% 2473
2022
Q4 		$29.7M Buy
2,812,965
+47,960
+2% +$583K ﹤0.01% 2439
2022
Q3 		$35.4M Buy
2,765,005
+19,486
+0.7% +$263K ﹤0.01% 2350
2022
Q2 		$35.2M Buy
2,745,519
+393,394
+17% +$4.46M ﹤0.01% 2361
2022
Q1 		$24.6M Sell
2,352,125
-14,683
-0.6% -$198K ﹤0.01% 2656
2021
Q4 		$36.5M Buy
2,366,808
+85,357
+4% +$1.7M ﹤0.01% 2524
2021
Q3 		$51.5M Buy
2,281,451
+1,125,686
+97% +$30.1M ﹤0.01% 2347
2021
Q2 		$29.8M Buy
1,155,765
+4,478
+0.4% +$138K ﹤0.01% 2635
2021
Q1 		$48M Buy
+1,151,287
New +$46.7M ﹤0.01% 2339

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Vanguard Group's CGEM Position: Q4 2025 in Review

Vanguard Group increased its Cullinan Oncology (CGEM) stake by 12% in Q4 2025, buying an estimated $3.2M and bringing the position to 3,298,504 shares worth $34.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2372.

Vanguard Group first reported a position in CGEM in Q1 2021 and has held it in 20 quarters since. The position peaked at $51.5M in Q3 2021. 153 funds tracked by Wall St. Rank hold CGEM as of Q4 2025.

  • Vanguard Group held 3,298,504 shares of Cullinan Oncology worth $34.1M as of Q4 2025.
  • Vanguard Group bought 355,179 Cullinan Oncology shares in Q4 2025, an estimated $3.2M.
  • Cullinan Oncology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2372 holding.
  • Vanguard Group first reported a position in Cullinan Oncology in Q1 2021 and has held it in 20 quarters since.
  • Vanguard Group's Cullinan Oncology position peaked at $51.5M in Q3 2021.
  • 153 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.